(FILE 'HOME' ENTERED AT 06:46:05 ON 16 DEC 1999)

FILE 'CAPLUS, MEDLINE, BIOSIS, SCISEARCH, EMBASE, EUROPATFULL, USPATFULL'
ENTERED AT 06:46:52 ON 16 DEC 1999
ACTIVATE L09400343/L

```
L1  (     14793)SEA PACLITAXEL
L2  (     15348)SEA POVIDONE
L3  (     22993)SEA (OLEIC ACID MONOESTER) OR (STEARIC ACID MONOESTER) OR (RICI
L4  (     56706)SEA (OXYETHYLENE SORBITOL OLEATE) OR (OLEATE)
L5  (    491680)SEA (POLYETHYLENE GLYCOL) OR (GLYCOL)
L6  (    746722)SEA (ANHYDROUS ALCOHOL) OR ALCOHOL
L7  (      6775)SEA TETRAOLEATE OR TRIOLEATE
L8  (         0)SEA L1 AND L2 AND L3 AND L4 AND L5 AND L6
L9  (         0)SEA (TAXAN? OR TAXOL?) AND L2 AND L3 AND L4 AND L5 AND L6
L10 (        27)SEA (TAXAN? OR TAXOL? OR ?TAXEL) AND L2
L11 (         0)SEA L10 AND (L3)
L12 (        13)SEA L10 AND L4
L13(        22)SEA L10 AND L5
L14(        25)SEA L6 AND L10
L15(        15)SEA L10 AND (MONOESTER OR ?ESTER)
L16(        12)SEA L15 AND L12
L17(        12)SEA L16 AND L13
L18(        12)SEA L17 AND L14
L19(        12)DUP REM L18 (0 DUPLICATES REMOVED)
L20(         2)SEA L10/CLM
L21(     37664)SEA ?TAXOL? OR ?TAXEL? OR TAXANE
L22(       356)SEA (?TAXOL? OR ?TAXEL? OR TAXANE)/CLM
L23(       103)SEA L22 AND L5
L24(         5)SEA L23 AND L2
L25(         0)SEA L24 AND L3
L26(         5)SEA L24 AND L5
L27(         5)SEA L24 AND L6
L28(         0)SEA L24 AND L7
L29(         1)SEA (?TAXEL)/CLM
L30(        81)SEA L1/CLM
L31(        16)SEA L30 AND (L2/CLM OR L3/CLM OR L4/CLM OR L5/CLM OR L6/C
               ---------
L32           3 S L21 (30A) ( (OLEIC POLYESTER) OR OLEATE OR (OLEIC ACID))
L33           0 S L32 AND L5
L34           1 S L32 AND ( FATTY ACID)
L35      170994 S OLEATE OR STEARATE OR RICINOLEATE
L36          15 S L21 (100A) L35
L37           8 S L21 (100A) ( (OLEIC POLYESTER) OR OLEATE OR (OLEIC ACID))
L38           5 S (L36 OR L37) AND L22
```

```
     FILE 'CAPLUS, MEDLINE, BIOSIS, SCISEARCH, EMBASE, EUROPATFULL,
USPATFULL'
     ENTERED AT 06:46:52 ON 16 DEC 1999
                ACTIVATE L09400343/L
                ---------
L1  (     14793)SEA PACLITAXEL
L2  (     15348)SEA POVIDONE
L3  (     22993)SEA (OLEIC ACID MONOESTER) OR (STEARIC ACID MONOESTER) OR (RICI
L4  (     56706)SEA (OXYETHYLENE SORBITOL OLEATE) OR (OLEATE)
L5  (    491680)SEA (POLYETHYLENE GLYCOL) OR (GLYCOL)
L6  (    746722)SEA (ANHYDROUS ALCOHOL) OR ALCOHOL
L7  (      6775)SEA TETRAOLEATE OR TRIOLEATE
L8  (         0)SEA L1 AND L2 AND L3 AND L4 AND L5 AND L6
L9  (         0)SEA (TAXAN? OR TAXOL?) AND L2 AND L3 AND L4 AND L5 AND L6
L10 (        27)SEA (TAXAN? OR TAXOL? OR ?TAXEL) AND L2
L11 (         0)SEA L10 AND (L3)
L12 (        13)SEA L10 AND L4
L13(        22)SEA L10 AND L5
L14(        25)SEA L6 AND L10
L15(        15)SEA L10 AND (MONOESTER OR ?ESTER)
L16(        12)SEA L15 AND L12
L17(        12)SEA L16 AND L13
L18(        12)SEA L17 AND L14
L19(        12)DUP REM L18 (0 DUPLICATES REMOVED)
L20(         2)SEA L10/CLM
L21(     37664)SEA ?TAXOL? OR ?TAXEL? OR TAXANE
L22(       356)SEA (?TAXOL? OR ?TAXEL? OR TAXANE)/CLM
L23(       103)SEA L22 AND L5
L24(         5)SEA L23 AND L2
L25(         0)SEA L24 AND L3
L26(         5)SEA L24 AND L5
L27(         5)SEA L24 AND L6
L28(         0)SEA L24 AND L7
L29(         1)SEA (?TAXEL)/CLM
L30(        81)SEA L1/CLM
L31(        16)SEA L30 AND (L2/CLM OR L3/CLM OR L4/CLM OR L5/CLM OR L6/C
                ---------
L32           3 S L21 (30A) ( (OLEIC POLYESTER) OR OLEATE OR (OLEIC ACID))
L33           0 S L32 AND L5
L34           1 S L32 AND ( FATTY ACID)
L35      170994 S OLEATE OR STEARATE OR RICINOLEATE
L36          15 S L21 (100A) L35
L37           8 S L21 (100A) ( (OLEIC POLYESTER) OR OLEATE OR (OLEIC ACID))
L38           5 S (L36 OR L37) AND L22
                SAVE L32-38 L19400343/L
L39           4 S L38 AND L23
L40           0 S L38 AND L15
L41          68 S L2 AND L21
L42           0 S L41 AND L32
L43          25 S L41 AND L35
L44           3 S L43 AND L22
L45           0 S L44 AND (MONOESTER OR (MONO ESTER))
```

```
     ACTIVATE L09400343/L
                ---------
L1  (     14793)SEA PACLITAXEL
L2  (     15348)SEA POVIDONE
L3  (     22993)SEA (OLEIC ACID MONOESTER) OR (STEARIC ACID MONOESTER) OR (RICI
L4  (     56706)SEA (OXYETHYLENE SORBITOL OLEATE) OR (OLEATE)
L5  (    491680)SEA (POLYETHYLENE GLYCOL) OR (GLYCOL)
L6  (    746722)SEA (ANHYDROUS ALCOHOL) OR ALCOHOL
L7  (      6775)SEA TETRAOLEATE OR TRIOLEATE
L8  (         0)SEA L1 AND L2 AND L3 AND L4 AND L5 AND L6
L9  (         0)SEA (TAXAN? OR TAXOL?) AND L2 AND L3 AND L4 AND L5 AND L6
L10 (        27)SEA (TAXAN? OR TAXOL? OR ?TAXEL) AND L2
L11 (         0)SEA L10 AND (L3)
L12 (        13)SEA L10 AND L4
L13(        22)SEA L10 AND L5
L14(        25)SEA L6 AND L10
L15(        15)SEA L10 AND (MONOESTER OR ?ESTER)
L16(        12)SEA L15 AND L12
L17(        12)SEA L16 AND L13
L18(        12)SEA L17 AND L14
L19(        12)DUP REM L18 (0 DUPLICATES REMOVED)
L20(         2)SEA L10/CLM
L21(     37664)SEA ?TAXOL? OR ?TAXEL? OR TAXANE
L22(       356)SEA (?TAXOL? OR ?TAXEL? OR TAXANE)/CLM
L23(       103)SEA L22 AND L5
L24(         5)SEA L23 AND L2
L25(         0)SEA L24 AND L3
L26(         5)SEA L24 AND L5
L27(         5)SEA L24 AND L6
L28(         0)SEA L24 AND L7
L29(         1)SEA (?TAXEL)/CLM
L30(        81)SEA L1/CLM
L31(        16)SEA L30 AND (L2/CLM OR L3/CLM OR L4/CLM OR L5/CLM OR L6/C
                ---------
L32           3 S L21 (30A) ( (OLEIC POLYESTER) OR OLEATE OR (OLEIC ACID))
L33           0 S L32 AND L5
L34           1 S L32 AND ( FATTY ACID)
L35      170994 S OLEATE OR STEARATE OR RICINOLEATE
L36          15 S L21 (100A) L35
L37           8 S L21 (100A) ( (OLEIC POLYESTER) OR OLEATE OR (OLEIC ACID))
L38           5 S (L36 OR L37) AND L22
                SAVE L32-38 L19400343/L
L39           4 S L38 AND L23
L40
```

L31 ANSWER 1 OF 16 EUROPATFULL COPYRIGHT 1999 WILA

CLMEN 1. A stabiliser formulation for use in combination with, and as a vehicle for, **paclitaxel** to form a pharmaceutical for use in treating cancer said formulation comprising polyethoxylated castor oil and an acidifying agent.

4. A formulation as claimed in claim 1 and comprising:-

(i) polyethoxylated castor oil as a solubilizer for **paclitaxel**,

(ii) citric acid as an acidifying agent, and

(iii) optionally ethanol

5. A composition comprising:-

paclitaxel;

castor oil; and

anhydrous citric acid in sufficient amounts to adjust the pH of the composition to less. . .

6. A pharmaceutical composition suitable for use in treating cancer and comprising **paclitaxel**, polyethoxylated castor oil and an acidifying agent, the components of the composition being mixed in such proportion that said composition. . .

8. A pharmaceutical composition as claimed in claim 6 or claim 7 and including ethanol or other **alcohol** as a constituent thereof.

13. A pharmaceutical composition as claimed in claim 6 and comprising:-

(i) **paclitaxel**;

(ii) polyethoxylated castor oil as a solubilizer for the **paclitaxel**;

(iii) citric acid as an acidifying agent present in such an amount that the composition as a whole has. . .

14. Use of an acidifying agent as a stabilizer for **paclitaxel** in a pharmaceutical composition in which said **paclitaxel** is carried by polyethoxylated castor oil, said acidifying agent being employed in such use in such proportion that said composition. . .

18. Use as claimed in claim 14 wherein the acidified stabilized pharmaceutical composition comprises:-

(i) **paclitaxel**;

(ii) polyethoxylated castor oil as a solubilizer for **paclitaxel**;

(iii) citric acid as the acidifying agent, said acidifying agent being present in such an amount that the acidified. . .

19. Use of an acidifying agent for the manufacture of a medicament which comprises **paclitaxel** and polyethoxylated castor oil as well as said acidifying agent, which medicament has a pH less than 8.1 and which. . .

20. . . . medicament for use in the treatment of cancer, said medicament being in the form of a composition comprising citric acid, **paclitaxel** and polyethoxylated castor oil and having a pH of less than 8.1.

21. . . . comprising:-

(i) mixing an acid material with a carrier material to form a carrier solution; and

(ii) mixing **paclitaxel** with the carrier solution to form a **paclitaxel** solution having a pH of less than 8.1 whereby the **paclitaxel** in the **paclitaxel** solution does not readily degrade.

22. A method as claimed in claim 21 wherein said **paclitaxel** solution has a pH of from 5 to 7.

26. A method as claimed in any one of claims 21 to 25 and including the step of slurrying said **paclitaxel** in ethanol before mixing

(iii) citric acid as the acidifying agent, said acidifying agent being present in such an amount that acidified stabilized. . .

14. Use of an acidifying agent for the manufacture of a medicament which comprises **paclitaxel** and polyethoxylated castor oil as well as said acidifying agent, which medicament has a pH less than 8.1 and which. . .

15. Use of citric acid, **paclitaxel** and polyethoxylated castor oil for the manufacture of a medicament for use in the treatment of cancer, said medicament being in the form of a composition comprising citric acid, **paclitaxel** and polyethoxylated castor oil and having a pH of less than 8.1.

16. . . . comprising:-

(i) mixing an acid material with a carrier material to form a carrier solution; and

(ii) mixing **paclitaxel** with the carrier solution to form a **paclitaxel** solution having a pH of less than 8.1 whereby the **paclitaxel** in the **paclitaxel** solution does not readily degrade.

17. A method as claimed in Claim 16 wherein said **paclitaxel** solution has a pH of from 5 to 7.

21. A method as claimed in any one of Claims 16 to 20 and including the step of slurrying said **paclitaxel** in ethanol before mixing said **paclitaxel** with the carrier solution.

CLMDE 1. Eine pharmazeutische Zusammensetzung, geeignet zur Verwendung bei der Behandlung von Krebs und umfassend **Paclitaxel** (Taxol), polyethoxyliertes Castoroel und ein Saeuerungsmittel, wobei die Komponenten der Zusammensetzung in solchen Mengen vermischt werden, dass die Zusammensetzung einen. . .

8. Pharmazeutische Zusammensetzung, wie in Anspruch 1 beansprucht und umfassend:

(i) **Paclitaxel**,

(ii) polyethoxyliertes Castoroel als ein Loesungsvermittler fuer das **Paclitaxel**,

(iii) Zitronensaeure als ein Saeuerungsmittel, vorhanden in einer Menge, so dass die Zusammensetzung als ganzes einen pH-Wert von 1. . .

9. Die Verwendung eines Saeuerungsmittels als ein Stabilisator fuer **Paclitaxel** in einer pharmazeutischen Zusammensetzung, in der das **Paclitaxel** umgesetzt wird durch polyethoxyliertes Castoroel, wobei das Saeuerungsmittel derart und in solchen Teilen verwendet wird, dass die Zusammensetzung einen resultierenden. . .

13. Verwendung wie in Anspruch 9 beansprucht, wobei die angesaeuerte stabilisierte pharmazeutische Zusammensetzung umfasst:

(i) **Paclitaxel**,

(ii) polyethoxyliertes Castoroel als ein Loesungsvermittler fuer das **Paclitaxel**,

(iii) Zitronensaeure als das Saeuerungsmittel, wobei das Saeuerungsmittel in einer Menge vorhanden ist, so dass die angesaeuerte stabilisierte pharmazeutische. . .

15. Verwendung von Zitronensaeure, **Paclitaxel** und polyethoxyliertem Castoroel zur Herstellung eines Medikaments zur Verwendung bei der Behandlung von Krebs, wobei das Medikament in der Form einer Zusammensetzung ist, umfassend Zitronensaeure, **Paclitaxel** und polyethoxyliertes Castoroel und einen pH-Wert von weniger als 8,1 hat.

16. . . . Verfahren umfasst:

(i) Mischen eines sauren Materials mit einem Traegermaterial, zur Bildung einer Traegerloesung und

(ii) Mischen von **Paclitaxel** mit der Traegerloesung, um eine Paclitaxelloesung mit einem pH-Wert von weniger als 8,1 zu bilden,

wobei das **Paclitaxel** in der Paclitaxelloesung nicht ohne weiteres degeneriert.
21. Verfahren, wie in einem der Ansprueche 16 bis 20 beansprucht und den Schritt des Aufschlaemmens des **Paclitaxel** in Ethanol vor dem Beimischen des **Paclitaxel** zur Traegerloesung einschliesst.

CLMFR 1. Composition pharmaceutique appropriee pour une utilisation dans le traitement du cancer et comprenant du **paclitaxel** (taxol), de l'huile de ricin polyethoxyle et un agent acidifiant, les constituants de la composition etant melanges en une proportion. . .
8. Composition pharmaceutique selon la revendication 1, comprenant :
(i) du **paclitaxel**,
(ii) de l'huile de ricin polyethoxyle en tant qu'agent solubilisant pour le **paclitaxel**,
(iii) de l'acide citrique en tant qu'agent acidifiant en une quantite telle que la composition presente dans son ensemble. . .
9. Utilisation d'un agent acidifiant en tant qu'agent de stabilisation pour le **paclitaxel** dans une composition pharmaceutique dans laquelle ledit **paclitaxel** est vehicule par de l'huile de ricin polyethoxyle, ledit agent acidifiant etant employe en une quantite telle que ladite composition. . .
13. Utilisation selon la revendication 9, dans laquelle la composition pharmaceutique stabilisee acidifiee comprend :
(i) du **paclitaxel**,
(ii) de l'huile de ricin polyethoxyle en tant qu'agent solubilisant pour le **paclitaxel**,
(iii) de l'acide citrique en tant qu'agent acidifiant, ledit agent acidifiant etant present en une quantite telle que la. . .
14. Utilisation d'un agent acidifiant pour la fabrication d'un medicament comprenant du **paclitaxel** et de l'huile de ricin polyethoxyle ainsi qu'un agent acidifiant, ledit medicament presentant un pH inferieur a 8,1 et etant. . .
15. Utilisation d'acide citrique, de **paclitaxel** et d'huile de ricin polyethoxyle pour la fabrication d'un medicament destine au traitement du cancer, ledit medicament se presentant sous la forme d'une composition comprenant de l'acide citrique, du **paclitaxel** et de l'huile de ricin polyethoxyle et presentant un pH inferieur a 8,1.
16. . . . le melange d'un materiau acide avec un vehicule pour former une solution de vehicule; et
(ii) le melange du **paclitaxel** avec la solution de vehicule de facon a former un solution de **paclitaxel** presentant un pH inferieur a 8,1, ce par quoi le **paclitaxel** dans la solution de **paclitaxel** ne se decompose pas rapidement.
17. Procede selon la revendication 16, dans laquelle ladite solution de **paclitaxel** presente un pH de 5 a 7.
21. Procede selon l'une quelconque des revendications 16 a 20, comprenant l'etape consistant a mettre en suspension ledit **paclitaxel** dans le l'ethanol avant de melanger ledit **paclitaxel** avec la solution de vehicule.

PI EP 674510 B1 19980805

L31 ANSWER 4 OF 16 EUROPATFULL COPYRIGHT 1999 WILA

CLMEN 1. A stabilized composition comprising at least one pharmaceutical compound selected from the group consisting of **paclitaxel**, camptothecin and derivatives thereof; and
a solvent capable of dispersing or solubilizing said pharmaceutical compound, said solvent comprising an effective. . . agent having a carboxylate anion content sufficiently low to prevent catalyzed degradation of said pharmaceutical compound,
provided that compositions comprising **paclitaxel**, polyethoxylated castor oil and ethanol adjusted to a pH less than 8.1 by

addition of an acid other than HBr,. . .
2. A stabilized composition comprising at least one pharmaceutical compound selected from the group consisting of **paclitaxel**, camptothecin and derivatives thereof; and
a solvent capable of dispersing or solubilizing said pharmaceutical compound, said solvent comprising an effective. . .
6. The composition of any one of claims 1 to 5, wherein said solvent further comprises an **alcohol**, more specifically an **alcohol** selected from the group consisting of ethanol and **polyethylene glycol**.
7. The composition of claim 6, wherein said solvent is a mixture of ethyl **alcohol** and said polyoxyethylated castor oil in a ratio of about 50:50 by volume.

CLMDE 1. Stabilisierte Zusammensetzung umfassend mindestens eine pharmazeutische Verbindung ausgewaehlt aus der Gruppe bestehend aus **Paclitaxel**, Camptothecin und Derivaten davon; und
ein Loesemittel, das faehig ist, die pharmazeutische Verbindung zu dispergieren oder zu solubilisieren, wobei das. . . Gehalt an Carboxylatanion, der ausreichend niedrig ist, dass ein katalysierter Abbau der pharmazeutischen Verbindung verhindert ist,
vorausgesetzt, dass Verbindungen, die **Paclitaxel**, polyethoxyliertes Castoroel und Ethanol enthalten, eingestellt auf einen
pH von weniger als 8,1 durch Zugabe einer anderen Saeure als HBr,. . .
2. Stabilisierte Zusammensetzung umfassend mindestens eine pharmazeutische Verbindung ausgewaehlt aus der Gruppe bestehend aus **Paclitaxel**, Camptothecin und Derivaten davon; und
ein Loesemittel, das faehig ist, die pharmazeutische Verbindung zu dispergieren oder zu solubilisieren, wobei das. . .

CLMFR 1. Composition stabilisee comprenant au moins un compose pharmaceutique selectionne dans le groupe consistant en **paclitaxel**, camptothecine et leurs derives; et
un solvant capable de disperser ou de solubiliser ledit compose pharmaceutique, ledit solvant comprenant une. . . en anion carboxylate suffisamment faible pour empecher la degradation catalysee dudit compose pharmaceutique,
a condition que les compositions comprenant le **paclitaxel**, de l'huile de ricin polyethoxylee et de l'ethanol ajuste a un pH inferieur a 8,1 par addition d'un acide autre. . .
2. Composition stabilisee comprenant au moins un compose pharmaceutique selectionne dans le groupe consistant en **paclitaxel**, camptothecine et leurs derives; et
un solvant capable de disperser ou de solubiliser ledit compose pharmaceutique, ledit solvant comprenant une. . .
6. . . . ou ledit solvant contient de plus un alcool, plus particulierement un alcool selectionne dans le groupe consistant en ethanol et **polyethylene glycol**.

PI EP 645145 B1 19970312

L31 ANSWER 5 OF 16 USPATFULL

CLM What is claimed is:
. . . 6. The composition according to claim 1 wherein the water-miscible solvent is selected from the group consisting of ethanol, propylene **glycol**, a **polyethylene glycol**, benzyl **alcohol**, N,N-dimethyl acetamide, dimethyl isosorbide, dimethyl sulfoxide, glycerol, triacetin, glycerol formal and 1-methyl-2-pyrrolidinone and mixtures thereof.
. . . The composition according to claim 6 wherein the water-miscible solvent is selected from the group consisting of ethanol and propylene **glycol** and mixtures thereof.

8. The composition according to claim 7 wherein the water-miscible solvent is an ethanol/propylene **glycol** mixture.

. . . a 23-oxo or 23-imino derivative of an LL-F28249.alpha.-.lambda., a milbemycin, an avermectin, vitamin A, vitamin D, vitamin E, vitamin K, **paclitaxel**, flufenoxuron, teflubenzuron, pyriproxyfen and levamisole and mixtures thereof.

. . . about 5 to 15% w/v sucrose monolaurate, about 10 to 30% w/v ethanol, and about 60 to 80% w/v propylene **glycol**.

. . . a disaccharide monoC.sub.8 -C.sub.18 fatty acid ester, and the water-miscible solvent is selected from the group consisting of ethanol, propylene **glycol**, a **polyethylene glycol**, benzyl **alcohol**, N,N-dimethyl acetamide, dimethyl isosorbide, dimethyl sulfoxide, glycerol, triacetin, glycerol formal and 1-methyl-2-pyrolidinone and mixtures thereof.

. . . and sucrose monostearate and mixtures thereof, and the water-miscible solvent is selected from the group consisting of ethanol and propylene **glycol** and mixtures thereof.

. . . about 5 to 15% w/v sucrose monolaurate, about 10 to 30% w/v ethanol, and about 60 to 80% w/v propylene **glycol**.

PI US 5965603 19991012

L31 ANSWER 6 OF 16 USPATFULL
CLM What is claimed is:
11. The composition of claim 10, wherein said polyalkylene oxide comprises **polyethylene glycol**.

17. The composition of claim 1, wherein D is selected from the group consisting of **paclitaxel**, taxotere, camptothecin and podophyllotoxin.

18. The composition of claim 1, wherein D is a member of the group consisting of **paclitaxel** and taxotere and Y' is attached to the 2' position of said **paclitaxel**, taxane or taxotere residues.

33. The compound of claim 32, wherein said polyalkylene oxide comprises **polyethylene glycol**.

46. The compound of claim 45, wherein said polyalkylene oxide comprises **polyethylene glycol**.

PI US 5965566 19991012

L31 ANSWER 7 OF 16 USPATFULL
CLM What is claimed is:
5. A method of using the lcp-castor oil of claim 1 comprising dissolving the lcp-castor oil of claim 1 in sufficient dehydrated **alcohol** and adding thereto a sufficient amount of **paclitaxel** to arrive at a formulation having per ml, about 527 mg of the lcp-castor oil of claim 1, about 6 mg of **paclitaxel**, and about 49.7 v/v % dehydrated **alcohol**.

. . . of not greater than about 5.0 measured when 527 mg of the neat lcp-castor oil is dissolved in sufficient dehydrated **alcohol** to make 1 ml of solution and the resultant solution is diluted with 13.29 times the weight of such solution. . .
13. The formulation of claim 10 having an active agent selected from diclofenac and **paclitaxel**.

14. The formulation of claim 13 wherein **paclitaxel** is the

active agent.

. . . formulation of claim 14 comprising per ml of solution, about 527 mg of the lcp-castor oil, about 6 mg of **paclitaxel**, and about 49.7 v/v % dehydrated **alcohol**.

. . . wherein said substantially water-free polyethoxylated castor oil has a water content of not greater than about 1% and said dehydrated **alcohol** has a water content of not greater than about 1%.

. . . pH of not greater than about 5.0 when measured by diluting a portion of the polyethoxylated castor oil in dehydrated **alcohol** solution with 13.29 times (by weight) as much water.

27. The formulation of claim 26 wherein said carrier is dehydrated **alcohol** and said active agent is **paclitaxel**.

PI US 5925776 19990720

L31 ANSWER 8 OF 16 USPATFULL
CLM What is claimed is:
1. A pharmaceutical composition comprising: **paclitaxel**, acid, water, **alcohol**, a polyglycol ester of 12-hydroxystearic acid and **polyethylene glycol**, and one or more organic solvents.

4. The composition of claim 1 wherein the **alcohol** is selected from ethanol and benzyl **alcohol**.

5. The composition of claim 4 wherein the **alcohol** is ethanol.

8. A pharmaceutical composition comprising: **paclitaxel** in the range of about 0.3% to about 0.8% (w/w), anhydrous acid in the range of about 0.2% to about 0.5% (w/w), **alcohol** in the range of about 10% to about 50% (w/w), water in the range of about 0% to about 25% (w/w), a polyglycol ester of 12-hydroxystearic acid and **polyethylene glycol** in the range of about 40% to about 50% (w/w), and one or more organic solvents, wherein the total percent. . .

9. The composition of claim 8 comprising: about 0.5% to about 0.7% **paclitaxel**; about 0.25% to about 0.35% anhydrous citric acid; about 14% to about 16% dehydrated ethanol; about 8% to about 10%. . .

10. The composition of claim 9 comprising: 0.57% **paclitaxel**; 0.27% anhydrous citric acid; 15.1% dehydrated ethanol; 8.9% water; 47.3% Solutol; 9.1% triacetin; and 19.1% glycerol.

PI US 5922754 19990713

L31 ANSWER 9 OF 16 USPATFULL
CLM What is claimed is:
. . . actinomycin, bleomycin, duanorubicin, doxorubicin, epirubicin, mitomycin, methotrexate, fluorouracil, carboplatin, carmustine (BCNU), methyl-CCNU, cisplatin, etoposide, interferon, camptothecin and derivatives thereof, phenesterine, **paclitaxel** and derivatives thereof, taxotere and derivatives thereof, vinblastine, vincristine, tamoxifen, etoposide or piposulfan.

. . . or aryl halides having 1-30 carbon atoms, optionally having more than one halogen substituent, ketones having 3-30 carbon atoms, polyalkylene **glycol**, or combinations of any two or more thereof.

. . . to claim 13 wherein said synthetic polymers are selected from synthetic polyamino acids containing cysteine residues and/or disulfide

groups; polyvinyl **alcohol** modified to contain free sulfhydryl groups and/or disulfide groups; polyhydroxyethyl methacrylate modified to contain free sulfhydryl groups and/or disulfide groups;. . .
PI US 5916596 19990629

L31 ANSWER 10 OF 16 USPATFULL
CLM What is claimed is:
4. A liposome according to claim 1, wherein said hydrophilic polymer is selected from the group consisting of **polyethylene glycol**, polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, and polyvinyl **alcohol**.

6. A liposome according to claim 1, wherein said hydrophilic polymer is **polyethylene glycol** having a molecular weight of between about 300 daltons and about 10,000 daltons.

7. A liposome according to claim 1, wherein said hydrophilic polymer is **polyethylene glycol** having a molecular weight of between about 300 daltons and about 1,000 daltons.

8. A liposome according to claim 1, wherein said hydrophilic polymer is **polyethylene glycol** having a molecular weight of about 750 daltons.

. . . 1, wherein said active agent is selected from the group consisting of

doxorubicin, epirubicin, daunorubicin, vincristine, vinblastine, etoposide, ellipticine, camptothecin, **paclitaxel**, docetaxol, cisplatin, prednisone, methyl-prednisolone, and ibuprofen.

. . . bilayer membrane comprising vesicle-forming lipid and from about 1 mole percent to about 22 mole percent vesicle-forming lipid derivatized with **polyethylene glycol**, said active agent aggregated with lipid surfactant to form micelles, said micelles entrapped within the interior space of said liposome,. . .
15. A liposome according to claim 14, wherein said **polyethylene glycol** has a molecular weight of between about 300 daltons and about 10,000 daltons.

16. A liposome according to claim 14, wherein said **polyethylene glycol** has a molecular weight of about 750 daltons.

. . . 14, wherein said active agent is selected from the group consisting of doxorubicin, epirubicin, daunorubicin, vincristine, vinblastine, etoposide, ellipticine, camptothecin, **paclitaxel**, docetaxol, cisplatin, prednisone, methyl-prednisolone, camptothecin and ibuprofen.

. . . lipid bilayer membrane comprising a vesicle-forming lipid and from 1 mole percent to 22 mole percent vesicle-forming lipid derivatized with **polyethylene glycol**, said **polyethylene glycol** having a molecular weight of about 750 daltons, and containing a micellar preparation of **paclitaxel** entrapped within the interior liposomal space.

23. A method according to claim 22, wherein said hydrophilic polymer is selected from the group consisting of **polyethylene glycol**, polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, and polyvinyl **alcohol**.

25. A method according to claim 22, wherein said hydrophilic polymer is **polyethylene glycol** having a molecular weight of between about 300 daltons and about 10,000 daltons.

26. A method according to claim 22, wherein said hydrophilic polymer is **polyethylene glycol** having a molecular weight of

between about 300 daltons and about 1,000 daltons.

27. A method according to claim 22, wherein said hydrophilic polymer is **polyethylene glycol** having a molecular weight of about 750 daltons.

. . . 22, wherein said active agent is selected from the group consisting of doxorubicin, epirubicin, daunorubicin, vincristine, vinblastine, etoposide, ellipticine, camptothecin, **paclitaxel**, docetaxol, cisplatin, prednisone, methyl-prednisolone, and ibuprofen.

PI US 5882679 19990316

L31 ANSWER 11 OF 16 USPATFULL
CLM What is claimed is:
1. A pharmaceutical composition for parenteral administration consisting essentially of a taxane analog, dimethylacetamide, (DMA), **polyethylene glycol** (PEG) and an aqueous lipid emulsion.

2. The pharmaceutical composition of claim 1, wherein said taxane analog is **paclitaxel**.

7. A method of preparing a **paclitaxel** composition for intravascular administration comprisng the steps of: dissolving **paclitaxel** in DMA at a concentration of up to about 100 mg/ml; adding **polyethylene glycol** (PEG) to the **paclitaxel** solution at a ratio of DMA:PEG of about 1:3 (v/v) to achieve a **paclitaxel** stock formulation with a concentration of up to about 25 mg/ml **paclitaxel**; and adding an aqueous lipid emulsion to achieve a **paclitaxel** concentration of from about 1 to about 5 mg/ml.

9. A method of treating a **paclitaxel** sensitive tumor comprising: obtaining a pharmaceutical composition consisting essentially of **paclitaxel** dissolved in dimethylacetamide (DMA) and **polyethylene glycol** (PEG) at a ratio of DMA:PEG of about 1:3 (v/v) and finally dissolved in an aqueous lipid emulsion to achieve a final **paclitaxel** concentration of about 1 to 5 mg/ml; and contacting said tumor with said pharmaceutical composition.

13. A **paclitaxel** stock formulation consisting essentially of **paclitaxel** and dimethylacetamide:**polyethylene glycol** in a v/v ratio of 1:3.

14. The **paclitaxel** stock formulation of claim 13, wherein said **polyethylene glycol** has a molecular weight of about 400.

PI US 5877205 19990302

L31 ANSWER 12 OF 16 USPATFULL
CLM What is claimed is:
. . . of claim 1, wherein said hydrophilic region is selected from the group consisting of polyethers, polyalkylene oxides, polyols, poly(vinylpyrrolidine), poly(vinyl **alcohol**), poly(alkyl oxazolines), polysaccharides, carbohydrates, peptides, proteins and copolymers and mixtures thereof.

. . . compositions of claim 28, wherein said drug or bio-active agent is selected from the group of antibiotic agents consisting of **paclitaxel**, mechlorethamine, chlorambucil, cyclophosphamide,

melphalan, ifosfamide, methotrexate, 6-mercaptopurine, 5-fluorouracil, cytarabine, vinblastine, vincristine, etoposide, doxorubicin, daunomycin, bleomycin, mitomycin, carmustine, lomustine, cisplatin, interferon,. . .

PI US 5854382 19981229

L31 ANSWER 13 OF 16 USPATFULL

CLM What is claimed is:

11. The composition of claim 10, wherein said polyalkylene oxide comprises **polyethylene glycol**.

17. The composition of claim 1, wherein D is selected from the group consisting of **paclitaxel**, taxotere, camptothecin and podophyllotoxin.

18. The composition of claim 1, wherein D is a member of the group consisting of **paclitaxel**, taxane and taxotere and Y' is attached to the 2' position of said **paclitaxel**, taxane or taxotere.

28. The composition of claim 23, wherein R.sub.2 comprises a **polyethylene glycol**.

30. The composition of claim 28, wherein said **polyethylene glycol** has a molecular weight of from about 20,000 to about 80,000.

PI US 5840900 19981124

L31 ANSWER 14 OF 16 USPATFULL

CLM What is claimed is:

1. A **paclitaxel** composition comprising: (a) **paclitaxel** at between about 1 mg/mL and about 5 mg/mL; (b) surfactant at between about 10% and about 50% (vol/vol); and. . .

6. The composition according to claim 1, wherein the solvent is dehydrated **alcohol** propylene **glycol** or **polyethylene glycol**.

7. The composition according to claim 6, wherein the dehydrated **alcohol** is ethanol and the concentration is between about 30% and about 85% in the concentrate prior to dilution for administration. . .

8. The composition according to claim 7, wherein the **alcohol** concentration is between about 60% and about 80%.

9. The composition according to claim 8, wherein the **alcohol** concentration is about 75%.

11. The composition according to claim 10, wherein the preservative is benzyl **alcohol**.

12. A **paclitaxel** composition that includes **paclitaxel** at between about 0.5 mg/ml and about 1.5 mg/ml, a solvent at between about 12% and about 80% (vol/vol), and. . .

16. The composition according to claim 12, wherein the solvent is dehydrated **alcohol** and the surfactant is a polyoxyethylated oil.

PI US 5681846 19971028

L31 ANSWER 15 OF 16 USPATFULL

CLM What is claimed is:

. . . selected from the group consisting of triglyceride fatty acids or fatty acid salts of at least 8 carbon atoms, cetyl/stearyl **alcohol**, wax esters, guar gum, methyl cellulose, hydroxypropyl

ACCESSION NUMBER:	95:78209 USPATFULL
TITLE:	Compositions and methods for topical administration of pharmaceutically active agents
INVENTOR(S):	Mantelle, Juan A., Miami, FL, United States
PATENT ASSIGNEE(S):	Nover Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5446070	19950829
APPLICATION INFO.:	US 1993-112330	19930827 (8)

DISCLAIMER DATE: 20100810

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1991-813196, filed on 23 Dec 1991, now patented, Pat. No. US 5234957 which

is a continuation-in-part of Ser. No. US 1991-661827, filed on 27 Feb 1991, now abandoned

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Page, Thurman K.
ASSISTANT EXAMINER:	Azpuru, Carlos
LEGAL REPRESENTATIVE:	Foley & Lardner
NUMBER OF CLAIMS:	45
EXEMPLARY CLAIM:	1
LINE COUNT:	2434

CAS INDEXING IS AVAILABLE FOR THIS PATENT.